Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

Item
http://www.wikidata.org/entity/Q24658506
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.The role and therapeutic targeting of IL-6 in rheumatoid arthritis.JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.JAK inhibition in inflammatory bowel disease.Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.JAK inhibitors in dermatology: The promise of a new drug class.Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate.The Effect of Verapamil, a P-Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once-Daily JAK Inhibitor.Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects.European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Developments with investigational Janus kinase inhibitors for rheumatoid arthritis.A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate.
P2860

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

Item
http://www.wikidata.org/entity/Q24658506
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Efficacy and safety of the ora ...... ebo-controlled phase IIb study
@ast
Efficacy and safety of the ora ...... ebo-controlled phase IIb study
@en
Efficacy and safety of the ora ...... ebo-controlled phase IIb study
@nl
type
label
Efficacy and safety of the ora ...... ebo-controlled phase IIb study
@ast
Efficacy and safety of the ora ...... ebo-controlled phase IIb study
@en
Efficacy and safety of the ora ...... ebo-controlled phase IIb study
@nl
prefLabel
Efficacy and safety of the ora ...... ebo-controlled phase IIb study
@ast
Efficacy and safety of the ora ...... ebo-controlled phase IIb study
@en
Efficacy and safety of the ora ...... ebo-controlled phase IIb study
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
Efficacy and safety of the ora ...... ebo-controlled phase IIb study
@en
P2093
P2860
P304
P31
P356
10.1136/ANNRHEUMDIS-2015-208279
P407
P433
P478
P50
P577
P5875
P698
P921
P932